Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,590 recalls, newest first

Class II · Moderate risk

Clopidogrel Tablets

Failed dissolution specification -Two additional lots being recalled due to Out-of-Specification results observed for dissolution at 18th month stability testing.

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-671-31 D-0294-2019
Class III · Low risk

Absorica (Isotretinoin)

Subpotent Drug: Isotretinoin content results were lower than the specification limit obtained during routing product monitoring.

Terminated Wrong potency / content Sun Pharmaceutical Industries, Inc. NDC 10631-117-31 D-1207-2019
Class II · Moderate risk

Estradiol Tablets

Presence of foreign tablet/capsule: A single foreign tablet was found in pharmacy dispensed bottle of 30 Estradiol 2 mg tablets.

Terminated Particulate / foreign matter Epic Pharma, LLC NDC 42806-089-01 D-0297-2019
Class III · Low risk

Amlodipine and Olmesartan Medoxomil Tablets

Discoloration: This product is being recalled due to a confirmed pharmacist report that tablets from this lot were a pink color instead of cream (peach).

Terminated Failed specification Aurobindo Pharma USA Inc. NDC 65862-855-30 D-0289-2019
Class I · High risk

Phenylephrine HCl

Labeling: Label Error on Declared Strength: Label incorrectly lists concentration as "10 mcg per mL" rather than the correct concentration of "100 mcg per mL".

Terminated Labeling / mix-up Advanced Pharma Inc. D-0347-2019
Class III · Low risk

Aprepitant Capsules

Shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.

Terminated Failed specification Glenmark Pharmaceuticals Inc., USA NDC 68462-583-40 D-0349-2019
Class II · Moderate risk

Infants' Ibuprofen

Superpotent Drug: recalled lots may have higher concentration of ibuprofen.

Terminated Wrong potency / content Tris Pharma Inc. NDC 55319-250-23 D-0336-2019
Class II · Moderate risk

infants* IBUPROFEN

Superpotent Drug: recalled lots may have higher concentration of ibuprofen.

Terminated Wrong potency / content Tris Pharma Inc. NDC 49035-125-23 D-0335-2019
Class III · Low risk

Norepinephrine 8 mg

Incorrect excipient: Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium Chloride

Terminated Other QuVa Pharma, Inc. D-0295-2019

Recalls by year